Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis

Condition:   Multiple Sclerosis
Interventions:   Drug: temelimab 18 mg/kg;   Drug: temelimab 36 mg/kg;   Drug: temelimab 54 mg/kg;   Drug: Placebo
Sponsor:   GeNeuro Innovation SAS
Completed